Diagnostics (CODX) Stock
Virus test developer for respiratory diseases. Here's the price, business snapshot, and what's worth knowing about Diagnostics in November 2026.
Co-Diagnostics Inc (CODX) is a microcap molecular diagnostics company that develops and licences PCR-based tests using its proprietary CoPrimer technology. The business focuses on infectious disease diagnostics — most notably assays for respiratory viruses — and generates revenue through test kit sales, licensing agreements and contract research. With a market capitalisation around $16 million, CODX is small and can be volatile; earnings and contract timing can cause rapid share-price moves. Key investor considerations include regulatory approvals, laboratory adoption, supply-chain capacity and cash runway, since smaller diagnostics firms often face funding and commercialisation hurdles. Potential catalysts are new contracts, wider regulatory clearance and partnerships, while risks include competitive pressure, reimbursement dynamics and dilution from fundraising. This is educational information only and not personalised advice; investors should assess their own risk tolerance and perform further research.
Why You’ll Want to Watch This Stock
Small‑cap volatility
CODX’s microcap status can lead to big price swings on news or results; this creates opportunity but also higher risk and lower liquidity.
Diagnostic tech focus
Proprietary CoPrimer PCR assays are central to its offering; tech adoption and validation are key commercial levers, though outcomes are uncertain.
Partnerships and approvals
New regulatory clearances or distribution deals can drive growth, but regulatory hurdles and competitive bids may delay impact.
